<DOC>
	<DOCNO>NCT00644540</DOCNO>
	<brief_summary>The purpose research evaluate immunogenicity single dose Influenza Vaccines ( 0.5mL 0.25mL ) healthy child age 35 month 36 48 month . To evaluate safety tolerability single 0.25mL IM injection influenza vaccine healthy child age 35 month ; evaluate safety tolerability single 0.50mL IM injection influenza vaccine healthy child age 48 month .</brief_summary>
	<brief_title>Immunogenicity Safety Following Single Dose Influenza Vaccines Healthy Children Who Received Either One Other Vaccine ( Adjuvanted Sub-unit Influenza Vaccine Non-adjuvanted Split Virion Influenza Vaccine ) Previous V70P2 Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>child 48 month age , receive dose one two study vaccine previous V70P2 trial , whose parents/legal guardian give write informed consent prior study entry , good health determine : medical history , physical examination , clinical judgment investigator . Experience severe acute infectious disease month prior study start experience mild acute infection disease week prior study start ; Any severe acute respiratory disease infection require systemic antibiotic antiviral therapy ongoing resolve within 15 day prior study start ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) ; Fever ( define axillary temperature ≥ 38.0°C/rectal temperature ≥ 38.5°C ) within 7 day enrolment ; Any serious disease include , example : cancer , autoimmune disease ( include rheumatoid arthritis ) , diabetes mellitus , chronic pulmonary disease , acute progressive hepatic disease , acute progressive renal disease ; Known suspect impairment/alteration immune function , example , result : receipt immunosuppressive therapy ( corticosteroid except topical inhaled steroid cancer chemotherapy ) , receipt immunostimulants , receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within past 3 month full length study , high risk develop immunocompromising disease ; Bleeding diathesis ; History hypersensitivity component study medication chemically related substance ; History anaphylaxis , serious vaccine reaction , allergy egg , egg product vaccine component ; Laboratory confirm influenza disease past 6 month ; Surgery plan study period ; Receipt another investigational vaccine investigational agent within 30 day prior study start . All routine vaccine give accord local recommendation : routine vaccine vaccine foreseen protocol give active trial phase ( i.e . 4 week last vaccination respective season ) conclude ; Participation another trial investigational agent within 90 day enrolment ; Any condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>16 Months</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>vaccine</keyword>
	<keyword>child</keyword>
</DOC>